Magnesium Supplementation Modulates T-cell Function in People with Type 2 Diabetes and Low Serum Magnesium Levels.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The researchers performed multidimensional immunophenotyping to better understand the effect of magnesium supplementation on the immune system of people with type 2 diabetes and low magnesium levels.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

In the crossover set-up each of the participants took both Vitamin D, K2, Magnesium and Zinc and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Magnesium, Dietary Supplements, Magnesium Deficiency, T-Lymphocytes and CD8-Positive T-Lymphocytes.

Author keywords: T-cells, inflammation and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.